Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.
about
Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients.The choreography of HIV-1 proteolytic processing and virion assemblyRelative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon SystemCombining mutations in HIV-1 protease to understand mechanisms of resistanceHIV-1 Protease with 20 Mutations Exhibits Extreme Resistance to Clinical Inhibitors through Coordinated Structural RearrangementsMutations in HIV-1 gag and pol Compensate for the Loss of Viral Fitness Caused by a Highly Mutated ProteaseA novel substrate-based HIV-1 protease inhibitor drug resistance mechanismGag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness lossPolymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimenTransmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral loadEstimating HIV-1 fitness characteristics from cross-sectional genotype dataStrong Selection Significantly Increases Epistatic Interactions in the Long-Term Evolution of a ProteinDistinguishing HIV-1 drug resistance, accessory, and viral fitness mutations using conditional selection pressure analysis of treated versus untreated patient samples.Novel HIV-1 knockdown targets identified by an enriched kinases/phosphatases shRNA library using a long-term iterative screen in Jurkat T-cellsTransmission fitness of drug-resistant HIV revealed in a surveillance system transmission networkIdentification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance.Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.Fitness epistasis and constraints on adaptation in a human immunodeficiency virus type 1 protein regionGenotypic testing for human immunodeficiency virus type 1 drug resistance.Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.A multifaceted analysis of HIV-1 protease multidrug resistance phenotypesHIV-1 diversity after a class switch failure.Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay.Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication.Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.In Vivo validation of a bioinformatics based tool to identify reduced replication capacity in HIV-1.Evolution of drug-resistant viral populations during interruption of antiretroviral therapyInfectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infectionImpaired infectivity of ritonavir-resistant HIV is rescued by heat shock protein 90AB1.HIV Genetic Diversity and Drug Resistance.Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivityHIV cell-to-cell transmission requires the production of infectious virus particles and does not proceed through env-mediated fusion pores.Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacityTransmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications?Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern IndiaDrug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations.Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.
P2860
Q22242225-9484B3ED-4C24-4A09-938C-22293C68C9C2Q27009643-63AB33DB-5CF9-4FBE-98DA-C046389416BFQ27485441-131A48D9-B4C1-4512-95EB-306F4A1D6949Q27638993-9D195658-534D-40B4-A125-A87CEF5F23ADQ27677952-C08F3CD2-BD5A-4956-B8E8-3DF8DF649863Q27679341-9C842EFF-F9B7-4FEE-BB50-AD76384EB86FQ28469113-383FCD54-11EC-4D40-B01F-FBA82E01E8E5Q28474984-1E8449C1-6683-4AAB-8060-7914EF6CBB88Q28477151-C0D990A8-FC4E-4EC8-97A3-0879974786E1Q28478656-D87ADD9A-3431-4659-B4BC-45ACEB553171Q28544753-021E433D-0BA8-4ABD-9592-7D606EF95E76Q28551065-C31AAF5F-85D3-4262-B29A-09B7FED44881Q30483107-7F629AB3-B575-4A8A-B414-573C586BF127Q33533377-8F6F5F3C-812A-4339-8EC3-17B7A1781D8DQ33589187-D0F32333-BA06-4D47-B81F-536CC6F0217AQ33592125-C2889DCD-7ECD-47AC-AD13-2797FA03819BQ33737755-8E33B716-A042-40B4-A011-5FC8907EBED7Q33843040-CE65B98E-1A00-49C7-8F94-CBCC792D3CC6Q33853183-A712E847-56C5-4AFF-BDE8-4400040340CAQ33906239-0155F32C-3A81-49A1-9ABE-48F3D2322111Q34012585-995FFABA-4074-4F35-BCA4-20BC144A70D7Q34102058-AF9B302A-247A-4089-9A67-4FD2FD617A7CQ34399268-57B5CDD7-BE0A-4FDE-9E2F-5F2D35236E2AQ34434646-CCF04599-B221-4035-B498-FF6E0EB2FCF1Q34461427-C2CCF94C-9B85-44F6-BE29-0958E62030B5Q34489422-4C0C9C33-298B-435F-B737-92A8A05752B3Q34717892-D9F67B5E-3C20-4418-A0F2-F7BE7743C0D7Q34937254-15C1BB7D-0BAE-4651-833B-1D7BE02F975DQ34991044-4179FE16-5D4F-4B90-B37D-683357BCD1E5Q35077423-C2FFC962-D0B8-46EF-BAB0-F3021723DDE2Q35104695-5478E5FB-EB97-4729-9536-18C76FFA94A5Q35107346-02C4A63B-C596-4B90-BEF5-86C95087A9A9Q35260590-8BED6C7F-3CB2-4728-9B6E-347EEC86BB4EQ35689381-2559311C-7F25-4580-99AF-6BDDDF4BFBFBQ35826780-E3829A49-064E-4348-AD50-63CAF553B70EQ35950846-F0D688D4-B060-471C-A8AD-DDA86F5FAB86Q35959266-EEE4B075-EDA5-47B7-A9D2-34440E4A5464Q36607906-C0CDC67E-BD3C-42FC-9765-4290CDB686A4Q36658105-8B015F4B-B403-4824-B769-18C5796FE3A5Q36673315-0FC3C140-C164-4BCD-BF0B-CD97B41A60AE
P2860
Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Retracing the evolutionary pat ...... e and in the presence of drug.
@en
Retracing the evolutionary pat ...... e and in the presence of drug.
@nl
type
label
Retracing the evolutionary pat ...... e and in the presence of drug.
@en
Retracing the evolutionary pat ...... e and in the presence of drug.
@nl
prefLabel
Retracing the evolutionary pat ...... e and in the presence of drug.
@en
Retracing the evolutionary pat ...... e and in the presence of drug.
@nl
P2093
P2860
P1433
P1476
Retracing the evolutionary pat ...... e and in the presence of drug.
@en
P2093
P2860
P304
P356
10.1128/JVI.74.18.8524-8531.2000
P407
P577
2000-09-01T00:00:00Z